Schroders plc share price jumps on Nuveen’s £9.9bn takeover offer — 612p headline value, profits, and what’s next

February 12, 2026
Schroders plc share price jumps on Nuveen’s £9.9bn takeover offer — 612p headline value, profits, and what’s next

London, February 12, 2026, 11:18 GMT — Regular session

Shares in Schroders surged Thursday following a £9.9 billion ($13.5 billion) takeover deal with U.S. asset manager Nuveen. This marks one of the largest asset-management acquisitions across Europe, the Middle East, and Africa. Nuveen’s CEO described the move as a “massive transformational step.” 1

The deal arrives as active managers—those who select securities instead of following an index—grapple with fee pressure and a steady flow of assets into low-cost passive funds. Nuveen has been expanding its private markets presence and is aiming for greater scale and reach, according to the Wall Street Journal. 2

Schroders has been cutting costs and reorganizing segments of its business, with the offer coming as it releases its annual results. According to the Financial Times, Schroders pitched the deal as a quicker way to build a “public-to-private” platform, covering both listed markets and private assets like private credit and private equity. 3

Schroders (SDR.L) climbed to about 587.5 pence, gaining 28.6%, after hitting a high of 599.5 pence, per Hargreaves Lansdown data. The FTSE 100 inched up 0.26%. 4

Shareholders are set to receive 590 pence per share in cash under the proposed deal, plus “permitted dividends” up to 22 pence—these dividends, paid before the deal closes, won’t reduce the cash payout. Nuveen has locked in irrevocable commitments covering around 42% of Schroders shares and aims to wrap up the acquisition in Q4 2026, pending regulatory clearance and other conditions. Schroders chair Dame Elizabeth Corley expressed confidence that the move is the “right step for our shareholders, clients and people.” 5

Schroders saw its adjusted operating profit — which excludes certain one-offs — climb 25% in 2025 to £756.6 million. Meanwhile, statutory profit before tax rose 21%, reaching £673.8 million. Assets under management (AUM) hit a record £823.7 billion, and net new business swung to £11.2 billion in inflows, a turnaround from outflows the previous year. CEO Richard Oldfield said the company had “returned to growth” but stayed “disciplined and clear-eyed” about the challenges ahead. 6

Despite the jump, the stock price remained under the 612 pence headline figure that factors in dividends, showing a slight deal-risk discount. Traders usually interpret that gap as a blend of timing, deal terms, and uncertainty over how much of the dividend will be paid out before the deal closes.

Analysts remain divided on whether the price fully reflects the company’s turnaround. RBC described the offer as compelling, noting potential implications for the broader listed asset-management sector. On the other hand, Panmure Liberum’s Rae Maile cautioned that the bid “came too soon” amid Schroders’ ongoing change programme. 7

Obvious risks remain: regulatory hold-ups, clients leaving amid a drawn-out closing process, or a market downturn that dampens risk appetite and complicates major integrations. Any shift in the approval timeline could push the discount on the offer value even wider.

Investors will be keeping an eye on the dividend schedule as takeover documents come into play. Schroders’ board has proposed a final dividend of 15.0 pence, with a record date set for March 13, 2026, and the payment expected on April 23, 2026. 8

Stock Market Today

  • 2 ASX Shares to Consider Buying in April 2026 Amid Market Uncertainty
    March 30, 2026, 11:44 PM EDT. Amid fluctuating ASX share prices, two standout investments emerge: Pro Medicus Ltd (PME) and the VanEck Morningstar Wide Moat ETF (MOAT). Pro Medicus, despite a 60% drop since September 2025, showcases strong fundamentals with a 28.4% revenue increase and a robust 72.6% EBIT margin for HY26, underlying profit growth, and a 28% rise in interim dividends. Valued at 80x estimated FY26 earnings, it remains a high-margin player in medical imaging software. The MOAT ETF provides diversified exposure to US companies with durable economic moats, focusing on long-term competitive advantages like brand power and intellectual property. Holding 57 stocks, including Bristol-Myers Squibb and Mondelez, MOAT has delivered an average annual return of 15.3% over the past decade, appealing to investors seeking stability during uncertain inflation and geopolitical periods.